- Price
- $1,116.11
- Day
- -0.47%
- Mkt Cap
- $1.05T
- 52W Range
- $623.78 – $1,249.45
- Volume
- 3.14M
- Beta
- 0.51
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Despite its relatively modest gains this year, Eli Lilly is still one of the most widely followed pharmaceutical stocks. Investors have already priced in strong growth for Mounjaro and Zepbound, making further progress with the triple-agonist retatrutide the next potential catalyst.
Read full article
Earnings are set to hit the tape in a tight window on Wednesday and the options market is already sketching out how much volatility traders are willing to pay for into the prints, according to Benzinga Pro.
Read full article
Eli Lilly and Company (NYSE:LLY) will release its second-quarter earnings report before the opening bell on Wednesday, Aug. 5.
Read full article
Eli Lilly is scheduled to report earnings Wednesday morning, with traders expecting the drugmaker's stock could potentially approach last month's highs following the results.
Read full article
HIGHLIGHTS Amplia has executed a Clinical Trial Collaboration & Supply Agreement (CTCSA) with Eli Lilly & Company, to evaluate the Company's investigational FAK inhibitor narmafotinib in combination with Lilly's late‑stage investigational next generation KRAS inhibitor olomorasib The collaboration is underpinned by narmafotinib's growing base of clinical evidence and a strong scientific rationale that FAK activation is a key driver of resistance to KRAS G12C inhibitors The collaboration further extends narmafotinib beyond pancreatic and ovarian cancer into NSCLC, broadening Amplia's clinical footprint and addressable opportunity Melbourne, Australia, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), announces that it has entered into a Clinical Trial Collaboration and Supply Agreement (“CTCSA”) with Eli Lilly & Company (“Lilly”), to evaluate the combination of Amplia's investigational FAK inhibitor, narmafotinib, with Lilly's investigational KRAS G12C inhibitor, olomorasib. The Phase 1b/2b clinical trial will evaluate the safety and efficacy of this novel targeted therapy combination as a second line treatment in patients with advanced stage non-small cell lung cancer (NSCLC).
Read full article
Eli Lilly and Company (NYSE: LLY - Get Free Report) is projected to announce its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Eli Lilly and Company to post earnings of $6.06 per share and revenue of $20.6851 billion for the quarter. Interested persons can find conference call details on the
Read full article
First National Bank of Mount Dora Trust Investment Services trimmed its position in Eli Lilly and Company (NYSE: LLY) by 21.3% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,440 shares of the company's stock after selling
Read full article
Stock futures are pointing to a higher open to kick off August trading as investors look ahead to a packed week of earnings reports; oil prices are tumbling after the U.S. paused strikes on Iran over the weekend; SpaceX is due to reports earnings for the first time this week, headlining a busy week of corporate results; Palantir is scheduled to release its earnings report after the closing bell today; and shares of AstraZeneca and Bristol-Myers Squibb are moving sharply following a report that the pharmaceutical giants have discussed a potential merger. Here's what you need to know today.
Read full article
INDIANAPOLIS, Aug. 3, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib as a monotherapy for the treatment of adult patients with advanced pancreatic cancer who have received at least one prior systemic therapy and have a KRAS G12C mutation, as determined by an FDA-approved test. Olomorasib is an investigational, potent and highly selective next-generation inhibitor of KRAS G12C.
Read full article
Eli Lilly said on Monday it would allow a limited number of patients to have early access to its experimental obesity drug, retatrutide, before its U.S. FDA approval.
Read full article
Novo Nordisk investors have found little cause for optimism during a bruising two-year period of profit warnings, leadership upheaval and a sliding share price as rival Eli Lilly streaked ahead. Now they may have reason for hope.
Read full article
US stock market is entering August against a turbulent backdrop, featuring continued Iran-driven volatility in oil prices and an ongoing earnings season. Plus, investors are still processing the recent Fed meeting where new chairman Kevin Warsh held benchmark rates steady.
Read full article